Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS103 in social anxiety disorder
NCT05429788Phase 1Withdrawn
- Sponsor
- Receptor Life Sciences
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in Social Anxiety Disorder (SAD) (3 arms), sponsored by Receptor Life Sciences. Primary endpoint: Incidence and severity of adverse events at 1 week. Planned start May 2022; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT05429788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429788.